ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 620

Efficacy of a Second Tumor Necrosis Factor Inhibitor (TNFi) in the Treatment of Rheumatoid Arthritis (RA)

Jennifer Reams1, Andrea Berger2, Philip Dunn2, Eva O'Connell3, William Torelli2, Jason Bankert2, Muhammed Bashir2 and Alfred Denio1, 1Rheumatology, Geisinger Medical Center, Danville, PA, 2Geisinger Medical Center, Danville, PA, 3Internal Medicine, Geisinger Medical Center, Danville, PA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Rheumatoid arthritis (RA), treatment and tumor necrosis factor (TNF)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The response rate of TNFis in RA is variable and to some extent unpredictable, making treatment decision-making quite complex.  Some insurance carriers require RA patients to have failed 2 different TNFi agents prior to a trial of a biologic agent with an alternate mechanism of action (MOA).  This study retrospectively analyzed our 4282 RA patient database to evaluate patients who failed to respond adequately to an initial TNFi and look for clinical predictors of response to a 2nd TNFi.

Methods: A retrospective manual chart review of the electronic health record (EHR) was performed on 322 RA patients seen over the course of four years who were noted to have been prescribed more than one TNFi.  Age, gender, body mass index (BMI), insurance provider, RA diagnosis length, cyclic citrullinated peptide antibody (CCP) and rheumatoid factor (RF) positivity, concomitant disease modifying anti-rheumatic drug (DMARD) therapy, length of time between diagnosis of RA and start of 1st and 2nd TNFi, efficacy of 1st and 2nd TNFi as evidenced by sustained or transient reduction in clinical disease activity index (CDAI) or impression of the treating rheumatologist, and reason for discontinuation were recorded.  Patients who did and did not respond to their 1st and 2nd TNFi were compared using Pearson’s chi-square or Fisher’s exact tests and Student’s t-tests or Wilcoxon rank-sum tests. Comparisons of responses to 1st and 2nd TNFis were made with McNemar’s tests.  A multivariable logistic regression model that included age, BMI, and statistically significant characteristics from the bivariate analysis was used to model response to a 2nd TNFi.

Results: Whether there was no response or transient achievement of response to a 1st TNFi as measured by CDAI or treating rheumatologist is displayed in Table 1.  RF positive patients were more likely to respond than RF negative patients.  Whether there was a transient response or not could not be determined in 5 patients (1.6%).  Response rates to the 2nd TNFi are displayed in Table 1.  Response to the 2nd TNFi could not be determined in 24 patients (7.5%).  Response rates to the 2nd TNFi were greater in females vs males and in RF positive vs. RF negative patients.  The predilection for female response was independent of age, BMI, and seropositivity.  If the time to 1st TNFi was three months or less from initial diagnosis of RA, sustained response to 2nd TNFi was more likely compared to longer times.

Conclusion: In RA patients who failed to achieve or sustain a clinical response to an initial TNFi, female patients, patients with +RF, and patients whose diagnosis of RA was within three months of 1st TNF initiation were more likely to have a clinical response to a 2nd TNF agent.  In the absence of these criterion, our data suggest a significantly reduced response to a 2nd TNFi .  In these individuals, a stronger consideration for choosing a biologic with alternative MOA could be given.


Disclosure: J. Reams, None; A. Berger, None; P. Dunn, None; E. O'Connell, None; W. Torelli, None; J. Bankert, None; M. Bashir, None; A. Denio, None.

To cite this abstract in AMA style:

Reams J, Berger A, Dunn P, O'Connell E, Torelli W, Bankert J, Bashir M, Denio A. Efficacy of a Second Tumor Necrosis Factor Inhibitor (TNFi) in the Treatment of Rheumatoid Arthritis (RA) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/efficacy-of-a-second-tumor-necrosis-factor-inhibitor-tnfi-in-the-treatment-of-rheumatoid-arthritis-ra/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-a-second-tumor-necrosis-factor-inhibitor-tnfi-in-the-treatment-of-rheumatoid-arthritis-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology